London-based AstraZeneca PLC has agreed to pay more than $5.5 million to resolve Securities and Exchange Commission allegations its subsidiaries bribed Chinese and Russian government officials—most of whom were health-care providers—to buy the company’s products (In re AstraZeneca PLC, SEC, Admin. Proc. File No. 3-17517, 8/30/16).
AstraZeneca employees in the China subsidiary also paid local officials to drop fines that were levied against it, the commission said. AstraZeneca was also accused of falsely recording the improper payments as bona fide business expenses in its consolidated financial statements.
U.S. law enforcement authorities have been investigating drugmakers in connection ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.